Literature DB >> 18366998

The metabolic syndrome in primary aldosteronism.

Francesco Fallo1, Giovanni Federspil, Franco Veglio, Paolo Mulatero.   

Abstract

Patients with hypertension have a high prevalence of concurrent metabolic abnormalities (eg, obesity, dyslipidemia, and hyperglycemia). Clustering of these risk factors, defined as the metabolic syndrome, is associated with a high cardiovascular risk profile. This review summarizes current knowledge about the prevalence and characteristics of the metabolic syndrome in primary aldosteronism, and discusses the possible pathophysiological link between aldosterone and individual components of the metabolic syndrome, other than hypertension. Impaired glucose metabolism due to insulin resistance appears to be the major contributor to metabolic dysfunction in primary aldosteronism. Experimental observations support the possibility that aldosterone could act directly on insulin receptor function. The potential proadipogenic role of aldosterone and its negative effect on insulin sensitivity through production of cytokines remains to be investigated. Higher rates of cardiovascular events reported in primary aldosteronism could be due in part to the increased prevalence of the metabolic syndrome in this disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18366998     DOI: 10.1007/s11892-008-0009-y

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  48 in total

1.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism.

Authors:  Francesco Fallo; Franco Veglio; Chiara Bertello; Nicoletta Sonino; Paolo Della Mea; Mario Ermani; Franco Rabbia; Giovanni Federspil; Paolo Mulatero
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

2.  Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity.

Authors:  M Haluzík; G Sindelka; J Widimský; M Prázný; T Zelinka; J Skrha
Journal:  J Hum Hypertens       Date:  2002-01       Impact factor: 3.012

3.  Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus?

Authors:  J Widimský; B Strauch; G Sindelka; J Skrha
Journal:  Physiol Res       Date:  2001       Impact factor: 1.881

4.  Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promonocytic cells.

Authors:  J Campión; B Maestro; F Mata; N Dávila; M C Carranza; C Calle
Journal:  J Steroid Biochem Mol Biol       Date:  1999 Sep-Oct       Impact factor: 4.292

5.  Plasma aldosterone is independently associated with the metabolic syndrome.

Authors:  Murielle Bochud; Jürg Nussberger; Pascal Bovet; Marc R Maillard; Robert C Elston; Fred Paccaud; Conrad Shamlaye; Michel Burnier
Journal:  Hypertension       Date:  2006-06-19       Impact factor: 10.190

Review 6.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

7.  Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes.

Authors:  D Kraus; J Jäger; B Meier; M Fasshauer; J Klein
Journal:  Horm Metab Res       Date:  2005-07       Impact factor: 2.936

Review 8.  The effect of aldosterone on glucose metabolism.

Authors:  Dalila B Corry; Michael L Tuck
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

9.  [Decreased insulin receptor number and affinity in subcutaneous adipose tissue in a patient with primary hyperaldosteronism].

Authors:  M C Carranza; A Torres; C Calle
Journal:  Rev Clin Esp       Date:  1991-05       Impact factor: 1.556

10.  Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion.

Authors:  Theodore L Goodfriend; Dennis L Ball; Brent M Egan; William B Campbell; Kasem Nithipatikom
Journal:  Hypertension       Date:  2004-01-12       Impact factor: 10.190

View more
  6 in total

1.  Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment.

Authors:  G Bernini; A Bacca; V Carli; D Carrara; G Materazzi; P Berti; P Miccoli; R Pisano; V Tantardini; M Bernini; S Taddei
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

2.  Differential effects of down-regulated steroidogenic factor-1 on basal and angiotensin II-induced aldosterone secretion.

Authors:  J Ouyang; D Hu; B Wang; T Shi; X Ma; H Li; X Wang; X Zhang
Journal:  J Endocrinol Invest       Date:  2011-10       Impact factor: 4.256

3.  Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat.

Authors:  Jayaraman Selvaraj; Sampath Sathish; Chinnaiyan Mayilvanan; Karundevi Balasubramanian
Journal:  Mol Cell Biochem       Date:  2012-09-25       Impact factor: 3.396

4.  Association of visceral adiposity and clinical outcome among patients with aldosterone producing adenoma.

Authors:  Leay Kiaw Er; Meng-Chun Lin; Yao-Chou Tsai; Jong-Kai Hsiao; Chung-Yi Yang; Chin-Chen Chang; Kang-Yung Peng; Jeff S Chueh; Vin-Cent Wu
Journal:  BMJ Open Diabetes Res Care       Date:  2020-07

5.  Plasma adrenocorticotropic hormone but not aldosterone is correlated with blood pressure in patients with aldosterone-producing adenomas.

Authors:  Hiroki Kobayashi; Akira Haketa; Ueno Takahiro; Hiromasa Otsuka; Sho Tanaka; Yoshinari Hatanaka; Yukihiro Ikeda; Masanori Abe; Noboru Fukuda; Masayoshi Soma
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-12-05       Impact factor: 3.738

6.  Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis.

Authors:  Rene Baudrand; Nidhi Gupta; Amanda E Garza; Anand Vaidya; Jane A Leopold; Paul N Hopkins; Xavier Jeunemaitre; Claudio Ferri; Jose R Romero; Jonathan Williams; Joseph Loscalzo; Gail K Adler; Gordon H Williams; Luminita H Pojoga
Journal:  J Am Heart Assoc       Date:  2016-09-28       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.